Clinical trial
Combination Chemotherapy Treatments in Patients With Metastatic Colorectal…
NCT00230399 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00230399 |
|---|---|
| Title | Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer |
| Official title | C-2424: Phase II Study of Celecoxib, Capecitabine, and Irinotecan in Patients With Metastatic Colorectal Cancer |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Celecoxib, Capecitabine, Irinotecan |
| Enrollment | 15 |
| Start date | Jun 1, 2003 |
| Primary completion | Jan 1, 2006 |
| Completion | Mar 1, 2008 |
| First posted | Sep 30, 2005 |
| Last update posted | Apr 21, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: